PharmaEssentia Corporation (TPE:6446)
1,400.00
0.00 (0.00%)
Aug 19, 2026, 1:30 PM CST
PharmaEssentia Revenue
PharmaEssentia had revenue of 6.86B TWD in the quarter ending June 30, 2026, with 90.30% growth. This brings the company's revenue in the last twelve months to 20.75B, up 64.25% year-over-year. In the year 2025, PharmaEssentia had annual revenue of 15.63B with 60.61% growth.
Revenue (ttm)
20.75B
Revenue Growth
+64.25%
P/S Ratio
27.96
Revenue / Employee
158.41M
Employees
131
Market Cap
580.20B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 15.63B | 5.90B | 60.61% |
| Dec 31, 2024 | 9.73B | 4.63B | 90.67% |
| Dec 31, 2023 | 5.11B | 2.22B | 77.15% |
| Dec 31, 2022 | 2.88B | 2.23B | 339.00% |
| Dec 31, 2021 | 656.51M | 99.25M | 17.81% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Lotus Pharmaceutical | 28.49B |
| Bora Pharmaceuticals | 19.56B |
| Grape King Bio | 10.28B |
| YungShin Global Holding | 7.84B |
| Standard Chemical & Pharmaceutical | 7.08B |
| TTY Biopharm Company | 6.65B |
| Synmosa Biopharma | 6.37B |
| ScinoPharm Taiwan | 3.07B |
PharmaEssentia News
- 7 days ago - PharmaEssentia Slides: Q2 2026 - Filings
- 3 months ago - PharmaEssentia Quarterly report: Q1 2026 - Filings
- 5 months ago - PharmaEssentia Quarterly report: Q4 2025 - Filings
- 7 months ago - PharmaEssentia Says FDA Accepts SBLA For ET Treatment Ropeginterferon Alfa-2b-njft - Nasdaq
- 9 months ago - PharmaEssentia Quarterly report: Q3 2025 - Filings
- 1 year ago - PharmaEssentia Quarterly report: Q2 2025 - Filings
- 1 year ago - ICC Arbitral Tribunal Rules in Favor of AOP Health in Arbitration Proceedings Pertaining to BESREMi® (Ropeginterferon alfa-2b) - Benzinga